Clinical Trial: Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
Study Status: Completed
Recruit Status: RECRUITING
Condition: Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder
Study Type: INTERVENTIONAL
Official Title: Phase II Study to Assess the Efficacy of Combined Tafasitamab and Rituximab in Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
Brief Summary:
This phase II trial tests how well tafasitamab and rituximab work for front-line treatment of patients with post-transplant lymphoproliferative disorder.Post-transplant lymphoproliferative disorder (PTLD) is the name for types of lymphoma that sometimes develop in people who have had a transplant.It can affect people who are taking medicines to suppress their immune system.Tafasitamab injection is in a class of medications called monoclonal antibodies.It works by helping the body to slow or stop the growth of…
Read more